SomaLogic, Inc. – NASDAQ:SLGC
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
SomaLogic stock price monthly change
-21.35%
month
SomaLogic stock price quarterly change
-7.08%
quarter
SomaLogic stock price yearly change
-7.08%
year
SomaLogic key metrics
Market Cap | 396.22M |
Enterprise value | N/A |
P/E | -5.16 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 3.69 |
Price/Book | 1.04 |
PEG ratio | N/A |
EPS | -0.69 |
Revenue | 81.72M |
EBITDA | -139.06M |
Income | -130.38M |
Revenue Q/Q | -47.14% |
Revenue Y/Y | -19.74% |
Profit margin | -96.68% |
Oper. margin | -157.97% |
Gross margin | 37.27% |
EBIT margin | -157.97% |
EBITDA margin | -170.16% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSomaLogic stock price history
SomaLogic stock forecast
SomaLogic financial statements
| Dec 2022 | 18.82M | -49.25M | -261.57% |
|---|---|---|---|
| Mar 2023 | 20.37M | -34.20M | -167.83% |
| Jun 2023 | 20.46M | -24.77M | -121.03% |
| Sep 2023 | 22.04M | -22.15M | -100.49% |
| 2025 | 116.76M | -83.8M | -71.77% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-11-08 | -0.17 | -0.12 |
|---|
| Dec 2022 | 647374000 | 84.81M | 13.1% |
|---|---|---|---|
| Mar 2023 | 614240000 | 78.93M | 12.85% |
| Jun 2023 | 585746000 | 70.59M | 12.05% |
| Sep 2023 | 565048000 | 68.30M | 12.09% |
| Dec 2022 | -34.72M | 75.92M | 300K |
|---|---|---|---|
| Mar 2023 | -43.04M | 55.27M | 172K |
| Jun 2023 | -26.23M | -57.97M | 250K |
| Sep 2023 | -21.36M | -27.57M | 0 |
SomaLogic alternative data
| Aug 2023 | 451 |
|---|---|
| Sep 2023 | 451 |
| Oct 2023 | 451 |
| Nov 2023 | 451 |
| Dec 2023 | 451 |
| Jan 2024 | 451 |
| Feb 2024 | 451 |
| Mar 2024 | 451 |
| Apr 2024 | 451 |
| May 2024 | 451 |
| Jun 2024 | 451 |
| Jul 2024 | 451 |
SomaLogic other data
34.45%
-30.08%
of SLGC is owned by hedge funds
83
-58
63.39M
-55.60M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 34229 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | TAICH ADAM officer: Interim CEO | Common Stock | 21,584 | $2.33 | $50,291 | ||
Sale | ROELKE ALISON MARIE officer: Chief Pe.. | Common Stock | 3,434 | $2.33 | $8,001 | ||
Sale | ROELKE ALISON MARIE officer: Chief Pe.. | Common Stock | 3,434 | $2.33 | $8,001 | ||
Sale | GUTIERREZ RUBEN officer: General Counsel | Common Stock | 9,211 | $2.33 | $21,462 | ||
Option | ROELKE ALISON MARIE officer: Chief Pe.. | Restricted Stock Unit (RSU) | 9,502 | N/A | N/A | ||
Option | ROELKE ALISON MARIE officer: Chief Pe.. | Restricted Stock Unit (RSU) | 9,502 | N/A | N/A | ||
Option | ROELKE ALISON MARIE officer: Chief Pe.. | Common Stock | 9,502 | N/A | N/A | ||
Option | ROELKE ALISON MARIE officer: Chief Pe.. | Common Stock | 9,502 | N/A | N/A | ||
Option | POST RICHARD A director: | Employee Stock Option (right to buy) | 1,586 | N/A | N/A | ||
Purchase | BARCHI ROBERT director | Common Stock, par value $0.0001 | 4,200 | $11.82 | $49,648 |
| Quarter | Transcript |
|---|---|
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 29 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Roy Smythe M.D. (1961) Chief Executive Officer & Director | $814,650 |
Ms. Melody Harris Esq., J.D. (1966) Pres & Chief Operating Officer | $682,780 |
Dr. Stephen A. Williams BS, MB, Ph.D. (1960) Chief Medical Officer | $557,130 |
-
When is SomaLogic's next earnings date?
Unfortunately, SomaLogic's (SLGC) next earnings date is currently unknown.
-
Does SomaLogic pay dividends?
No, SomaLogic does not pay dividends.
-
How much money does SomaLogic make?
SomaLogic has a market capitalization of 396.22M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.65% to 97.67M US dollars. SomaLogic made a loss 109.16M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.
-
What is SomaLogic's stock symbol?
SomaLogic, Inc. is traded on the NASDAQ under the ticker symbol "SLGC".
-
What is SomaLogic's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of SomaLogic?
Shares of SomaLogic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are SomaLogic's key executives?
SomaLogic's management team includes the following people:
- Dr. Roy Smythe M.D. Chief Executive Officer & Director(age: 64, pay: $814,650)
- Ms. Melody Harris Esq., J.D. Pres & Chief Operating Officer(age: 59, pay: $682,780)
- Dr. Stephen A. Williams BS, MB, Ph.D. Chief Medical Officer(age: 65, pay: $557,130)
-
How many employees does SomaLogic have?
As Jul 2024, SomaLogic employs 451 workers.
-
When SomaLogic went public?
SomaLogic, Inc. is publicly traded company for more then 4 years since IPO on 23 Apr 2021.
-
What is SomaLogic's official website?
The official website for SomaLogic is somalogic.com.
-
Where are SomaLogic's headquarters?
SomaLogic is headquartered at 2945 Wilderness Place, Boulder, CO.
-
How can i contact SomaLogic?
SomaLogic's mailing address is 2945 Wilderness Place, Boulder, CO and company can be reached via phone at +30 36259000.
SomaLogic company profile:
SomaLogic, Inc.
somalogic.comExchange:
NASDAQ
Full time employees:
451
Industry:
Medical - Healthcare Information Services
Sector:
Healthcare
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
2945 Wilderness Place
Boulder, CO 80301
Boulder, CO 80301
CIK: 0001837412
ISIN: US83444K1051
CUSIP: 83444K105
